Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Dechra Pharmaceuticals PLC (DE:1PK)
FRANKFURT:1PK
RESEARCH TOOLSreports
Dechra Pharmaceuticals (1PK) Stock Price & Analysis
3 Followers
1PK Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€28.00 - €45.20
Previous Close€44.4
Volume0.00
Average Volume (3M)121.00
Market Cap
€5.13B
Enterprise Value€5.63B
Total Cash (Recent Filing)£74.40M
Total Debt (Recent Filing)£504.50M
Price to Earnings (P/E)N/A
Beta0.69
Next Earnings
Feb 26, 2024EPS EstimateN/A
Last Dividend Ex-Date
Mar 09, 2023Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding113,888,190
10 Day Avg. Volume3
30 Day Avg. Volume121
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)-2619.70
Price to Sales (P/S)13.16
Price to Cash Flow (P/CF)-6518.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Dechra Pharmaceuticals News
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
0.11% Other Institutional Investors
99.89% Public Companies and
Individual Investors
1PK FAQ
What was Dechra Pharmaceuticals PLC’s price range in the past 12 months?
Dechra Pharmaceuticals PLC lowest stock price was €28.00 and its highest was €45.20 in the past 12 months.
What is Dechra Pharmaceuticals PLC’s market cap?
Currently, no data Available
When is Dechra Pharmaceuticals PLC’s upcoming earnings report date?
Dechra Pharmaceuticals PLC’s upcoming earnings report date is Feb 26, 2024 which is 69 days ago.
How were Dechra Pharmaceuticals PLC’s earnings last quarter?
Dechra Pharmaceuticals PLC released its earnings results on Oct 12, 2023. The company reported €0.454 earnings per share for the quarter, beating the consensus estimate of N/A by €0.454.
Is Dechra Pharmaceuticals PLC overvalued?
According to Wall Street analysts Dechra Pharmaceuticals PLC’s price is currently Overvalued.
Does Dechra Pharmaceuticals PLC pay dividends?
Dechra Pharmaceuticals PLC pays a Annually dividend of €0.15 which represents an annual dividend yield of N/A. See more information on Dechra Pharmaceuticals PLC dividends here
What is Dechra Pharmaceuticals PLC’s EPS estimate?
Dechra Pharmaceuticals PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Dechra Pharmaceuticals PLC have?
Currently, no data Available
What happened to Dechra Pharmaceuticals PLC’s price movement after its last earnings report?
Dechra Pharmaceuticals PLC reported an EPS of €0.454 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 1.835%.
Which hedge fund is a major shareholder of Dechra Pharmaceuticals PLC?
Currently, no hedge funds are holding shares in DE:1PK
---
Dechra Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
33.00%
12-Months-Change
Fundamentals
Return on Equity
-3.92%
Trailing 12-Months
Asset Growth
21.35%
Trailing 12-Months
Company Description
Dechra Pharmaceuticals PLC
Dechra Pharmaceuticals PLC is a major drug manufacturing company with a focus on veterinary pharmaceutical products. The company develops, manufactures, and markets its products exclusively for veterinarians globally. Dechra is structured along three segments, including being European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals Research and Development. The vast majority of Dechra's revenue is generated in Europe, followed by the U.S. Dechra derives most of its revenue through its Companion Animal Product category, followed by food-producing animal products.
---
1PK Stock 12 Months Forecast
Average Price Target
―Technical Analysis
Dechra Pharmaceuticals
―
C4X Discovery Holdings
―
ConvaTec
―
Allergy Therapeutics
―
Hikma Pharmaceuticals
―
Best Analysts Covering 1PK
1 Year
1 Year Success Rate
7/9 ratings generated profit
1 Year Average Return
+7.91%
reiterated a buy rating a year ago
Copying Anand Date's trades and holding each position for 1 Year would result in 77.78% of your transactions generating a profit, with an average return of +7.91% per trade.
---